Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission Intervention: Drug: Bortezomib Sponsors: Instituto do Cancer do Estado de São Paulo; Libbs Farmacêutica LTDA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Leukemia | Research | Velcade